{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:33:41Z","timestamp":1773938021219,"version":"3.50.1"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105083","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:19:52Z","timestamp":1765725592000},"page":"105083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epigenetic approaches to prostate cancer: Present landscape and future prospects"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-9263","authenticated-orcid":false,"given":"Konstantinos","family":"Mesiakaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthalia","family":"Kontogianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souzana","family":"Logotheti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Tzelepi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105083_bib1","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/j.annonc.2021.08.1099","article-title":"586P Safety of tazemetostat (TAZ) in combination with abiraterone\/prednisone (A\/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC","volume":"32","author":"Abida","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib2","first-page":"170","article-title":"Long non-coding RNA in prostate cancer","volume":"10","author":"An","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3816\/CGC.2010.n.006","article-title":"Future Directions in Castrate-Resistant Prostate Cancer Therapy","volume":"8","author":"Antonarakis","year":"2010","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1541-7786.MCR-15-0472","article-title":"BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer","volume":"14","author":"Asangani","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib5","first-page":"12","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","author":"Augert","year":"2019","journal-title":"Sci. Signal"},{"key":"10.1016\/j.critrevonc.2025.105083_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","article-title":"BET bromodomain inhibition of MYC-amplified medulloblastoma","volume":"20","author":"Bandopadhayay","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib7","doi-asserted-by":"crossref","unstructured":"Bayona-Feliu, A., Aguilera, A., 2021. The SWI\/SNF complex, transcription-replication conflicts and cancer: a connection with high therapeutic potential. https:\/\/doi.org\/10.1080\/23723556.2021.1976582.","DOI":"10.1080\/23723556.2021.1976582"},{"key":"10.1016\/j.critrevonc.2025.105083_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","article-title":"Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, p\u2026","volume":"18","author":"Beer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.clml.2021.06.020","article-title":"Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma","volume":"21","author":"Berdeja","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.105083_bib10","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (NCI Trial # 6862): Trial results and IL-6 analysis. A study by the DOD Prostate Cancer Clinical Trial Consortium and University of Chicago Phase II Consortium","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib11","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105083_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.trecan.2020.12.011","article-title":"Roles and Regulations of TET Enzymes in Solid Tumors","volume":"7","author":"Bray","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib13","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.3390\/cancers13205241","article-title":"Epigenetic Modifiers as Novel Therapeutic Targets and a Systematic Review of Clinical Studies Investigating Epigenetic Inhibitors in Head and Neck Cancer","volume":"13","author":"Burkitt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105083_bib14","series-title":"Medical Epigenetics","article-title":"Medical Epigenetics, Chapter 32 - Pharmacoepigenomics","author":"Cacabelos","year":"2016"},{"key":"10.1016\/j.critrevonc.2025.105083_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib16","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Cedazuridine","year":"2023"},{"key":"10.1016\/j.critrevonc.2025.105083_bib17","doi-asserted-by":"crossref","unstructured":"Chateauvieux, S., Morceau, F., Diederich, M., 2024. Valproic Acid. Encyclopedia of Toxicology, Fourth Edition: Volume 1-9 9, V9-705-V9-713. https:\/\/doi.org\/10.1016\/B978-0-12-824315-2.00578-9.","DOI":"10.1016\/B978-0-12-824315-2.00578-9"},{"key":"10.1016\/j.critrevonc.2025.105083_bib18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2019-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.105083_bib19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdw068","article-title":"A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11523-017-0546-x","article-title":"Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review","volume":"13","author":"Chovanec","year":"2018","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/B978-0-12-803239-8.00034-X","article-title":"Histone Deacetylase Inhibitors in Medical Therapeutics","author":"Chun","year":"2016","journal-title":"Med Epigenet"},{"key":"10.1016\/j.critrevonc.2025.105083_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2625","article-title":"Abstract 2625: Targeting prostate cancer stem cells (CSCs) with the novel BET bromodomain (BRD) protein inhibitor OTX015","volume":"75","author":"Civenni","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105083_bib24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.critrevonc.2025.105083_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-10-40","article-title":"Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer","author":"Crea","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-11-52","article-title":"The emerging role of histone lysine demethylases in prostate cancer","volume":"11","author":"Crea","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib27","first-page":"1","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-642-01222-8_10","article-title":"Decitabine","volume":"184","author":"Daskalakis","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105083_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0271-9","article-title":"Epigenetic polypharmacology: from combination therapy to multitargeted drugs","volume":"8","author":"de Lera","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib31","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ymthe.2025.02.045","article-title":"Clinical applications of oligonucleotides for cancer therapy","volume":"33","author":"DeFranciscis","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-03854-x","article-title":"Role of noncoding RNA in drug resistance of prostate cancer","volume":"12","author":"Ding","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.105083_bib34","unstructured":"Drugs Approved for Prostate Cancer - NCI [WWW Document], 2023. URL \u3008https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/prostate\u3009 (accessed 5.29.24)."},{"key":"10.1016\/j.critrevonc.2025.105083_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-11-A221","article-title":"Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC)","volume":"10","author":"Eigl","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib37","first-page":"15","article-title":"Drugging the epigenome in the age of precision medicine","author":"Feehley","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib38","article-title":"The Effect of a Small Molecule EZH2 Methyltransferase Inhibitor GSK126 on p53 Negative Prostate Cancer Cell Line","volume":"99","author":"Feng","year":"2017","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.105083_bib39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105083_bib40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","article-title":"Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells","volume":"8","author":"Fiskus","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1188\/12.CJON.195-204","article-title":"Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma","volume":"16","author":"Frye","year":"2012","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.critrevonc.2025.105083_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coph.2017.05.006","article-title":"Epigenetic modulation in cancer immunotherapy","volume":"35","author":"Gallagher","year":"2017","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/13543776.2014.859244","article-title":"BET bromodomain inhibitors: a patent review","volume":"24","author":"Garnier","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.critrevonc.2025.105083_bib46","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3390\/cells11132107","article-title":"Lysine-Specific Demethylase 1 (LSD1\/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis","volume":"11","author":"Gill","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.105083_bib47","first-page":"9","article-title":"3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells","author":"Girard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2025.105083_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"10.1016\/j.critrevonc.2025.105083_bib49","first-page":"8","article-title":"Epigenetic modulators as therapeutic targets in prostate cancer","author":"Gra\u00e7a","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/pros.20748","article-title":"Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells","volume":"68","author":"Gravina","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.105083_bib51","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.105083_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2147\/OTT.S33077","article-title":"Potential use of custirsen to treat prostate cancer","volume":"6","author":"Higano","year":"2013","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib53","first-page":"12","article-title":"Advances in Epigenetic Cancer Therapeutics","author":"Hillyar","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2025.105083_bib54","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1002\/cncr.34366","article-title":"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies","volume":"128","author":"Hollebecque","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib55","first-page":"4308","article-title":"DZNep inhibits Hif-1\u03b1 and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells","volume":"18","author":"Huang","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.105083_bib56","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.3390\/ijms222111596","article-title":"Ncrnas in therapeutics: Challenges and limitations in nucleic acid-based drug delivery","volume":"22","author":"Hueso","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105083_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01723-7","article-title":"Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition","volume":"39","author":"Iannelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13072-018-0203-3","article-title":"KDM1A microenvironment, its oncogenic potential, and therapeutic significance","volume":"11","author":"Ismail","year":"2018","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.critrevonc.2025.105083_bib59","doi-asserted-by":"crossref","unstructured":"Kanno, T., Kanno, Y., LeRoy, G., \u2026 E.C.-N. structural &, 2014, undefined, 2014. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. nature.comT Kanno, Y Kanno, G LeRoy, E Campos, HW Sun, SR Brooks, G Vahedi, TD HeightmanNature structural & molecular biology, 2014\u2022nature.com.","DOI":"10.1038\/nsmb.2912"},{"key":"10.1016\/j.critrevonc.2025.105083_bib60","doi-asserted-by":"crossref","first-page":"14522","DOI":"10.1021\/acs.jmedchem.0c00978","article-title":"Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)","volume":"63","author":"Kanouni","year":"2020","journal-title":"J. Med Chem."},{"key":"10.1016\/j.critrevonc.2025.105083_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115324","article-title":"TET protein inhibitors: Potential and limitations","volume":"166","author":"Kapl\u00e1nek","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2025.105083_bib62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.molonc.2013.01.003","article-title":"The lysine specific demethylase-1 (LSD1\/KDM1A) regulates VEGF-A expression in prostate cancer","volume":"7","author":"Kashyap","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib63","doi-asserted-by":"crossref","first-page":"16375","DOI":"10.3390\/ijms242216375","article-title":"Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins","volume":"24","author":"Kim","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105083_bib64","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.critrevonc.2025.105083_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01380","article-title":"Biomodulatory treatment with azacitidine, all-trans retinoic acid and pioglitazone induces differentiation of primary AML blasts into neutrophil like cells capable of ROS production and phagocytosis","volume":"9","author":"Klobuch","year":"2018","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1570159X17666191010094849","article-title":"Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application","volume":"18","author":"Kong","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib67","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1158\/1535-7163.MCT-19-0874","article-title":"Inhibition of EZH2 enhances the antitumor efficacy of metformin in prostate cancer","volume":"19","author":"Kong","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib68","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.3390\/cancers13133325","article-title":"Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response","volume":"13","author":"Kukkonen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105083_bib69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med Res Rev."},{"key":"10.1016\/j.critrevonc.2025.105083_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-32509-4","article-title":"DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors","volume":"13","author":"Laranjeira","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.105083_bib71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1590\/S1415-475738420150028","article-title":"Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1","volume":"38","author":"Lee","year":"2015","journal-title":"Genet Mol. Biol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib72","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib73","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01558-0","article-title":"Targeting the RNA m6A modification for cancer immunotherapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib75","first-page":"1","article-title":"Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.105083_bib76","doi-asserted-by":"crossref","first-page":"e2136","DOI":"10.1002\/onco.13957","article-title":"Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"26","author":"Lin","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.105083_bib77","first-page":"356","article-title":"Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells","volume":"45","author":"Lin","year":"2016","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"10.1016\/j.critrevonc.2025.105083_bib78","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.1073\/pnas.1216363109","article-title":"Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins","volume":"109","author":"Lockwood","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.105083_bib79","first-page":"15","article-title":"Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated \u201cOmics\u201d Approaches to Explore Measurable Metrics","author":"Logotheti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105083_bib80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molmed.2013.08.006","article-title":"Common non-epigenetic drugs as epigenetic modulators","volume":"19","author":"L\u00f6tsch","year":"2013","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.105083_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112355","article-title":"Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers","volume":"137","author":"Mamun","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13543784.2023.2186851","article-title":"Role of bromodomain and extraterminal (BET) proteins in prostate cancer","volume":"32","author":"Mandl","year":"2023","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.critrevonc.2025.105083_bib85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s40425-019-0758-y","article-title":"Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition","volume":"7","author":"Mao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib86","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/13543784.2017.1393518","article-title":"BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations","volume":"26","author":"Markowski","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.critrevonc.2025.105083_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175590","article-title":"Use of histone methyltransferase inhibitors in cancer treatment: A systematic review","volume":"944","author":"Marzochi","year":"2023","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib88","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","article-title":"Bromodomain inhibitors a decade later: a promise unfulfilled?","volume":"123","author":"Mita","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC","volume":"21","author":"Molife","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib90","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/ijms25073630","article-title":"Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review","volume":"25","author":"Nappi","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105083_bib91","first-page":"10","article-title":"Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma\u2014Progress and Challenges","author":"Nava","year":"2022","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105083_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib93","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Ott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105083_bib94","article-title":"Roles and therapeutic implications of m6A modification in cancer immunotherapy","volume":"14","author":"Pan","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib95","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.critrevonc.2025.105083_bib96","first-page":"10","article-title":"Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer","author":"Patnaik","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib97","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.105083_bib98","first-page":"4","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.critrevonc.2025.105083_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105083_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.680633","article-title":"Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers","volume":"12","author":"Punnia-Moorthy","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.critrevonc.2025.105083_bib102","first-page":"84","article-title":"Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.critrevonc.2025.105083_bib103","first-page":"8","article-title":"Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer","author":"Rana","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.105083_bib104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","article-title":"A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer","volume":"66","author":"Rathkopf","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib106","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","article-title":"MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside","volume":"15","author":"Ratti","year":"2020","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib107","doi-asserted-by":"crossref","first-page":"84675","DOI":"10.18632\/oncotarget.13181","article-title":"OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations","volume":"7","author":"Riveiro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105083_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-019-0675-4","article-title":"Epigenetics in cancer therapy and nanomedicine","volume":"11","author":"Roberti","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib109","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105083_bib110","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023012062","article-title":"Guadecitabine vs TC in relapsed\/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial","author":"Roboz","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.105083_bib111","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41416-018-0087-9","article-title":"Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2","volume":"118","author":"Rosenberg","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib112","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-11-0859","article-title":"Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","volume":"17","author":"Saad","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105083_bib113","first-page":"11","article-title":"Epigenetic reprogramming by TET enzymes impacts co-transcriptional R-loops","author":"Sabino","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2025.105083_bib114","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2022-168945","article-title":"Iadademstat combination with azacitidine is a safe and effective treatment in first line acute myeloid leukemia. final results of the alice trial","volume":"140","author":"Salamero","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105083_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib116","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2025.105083_bib117","first-page":"13","article-title":"Tracing TET1 expression in prostate cancer: discovery of malignant cells with a distinct oncogenic signature","author":"Schagdarsurengin","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib118","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijcard.2016.06.012","article-title":"Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research","volume":"219","author":"Schiattarella","year":"2016","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib119","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105083_bib120","doi-asserted-by":"crossref","first-page":"E4179","DOI":"10.1073\/pnas.1719168115","article-title":"LSD1 activates a lethal prostate cancer gene network independently of its demethylase function","volume":"115","author":"Sehrawat","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.105083_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115200","article-title":"Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer","volume":"404","author":"Shankar","year":"2020","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib122","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib123","first-page":"8","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.105083_bib124","first-page":"42","article-title":"5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-\u03b2-SMAD4 signaling","author":"Singh","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.105083_bib125","first-page":"682","article-title":"Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemona\u00efve castration-resistant prostate cancer","volume":"29","author":"Sonpavde","year":"2011","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2025.105083_bib126","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105083_bib127","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0518","article-title":"A randomized, double-blinded, phase ii trial of carboplatin and pemetrexed with or without apatorsen (OGX-427) in patients with previously untreated stage IV non-squamous-non-small-cell lung cancer: the SPRUCE trial","volume":"24","author":"Spigel","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.105083_bib128","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.3390\/cancers14215251","article-title":"HDACi: the columbus\u2019 egg in improving cancer treatment and reducing neurotoxicity?","volume":"14","author":"Squarzoni","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105083_bib129","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib130","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105083_bib131","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ijc.33375","article-title":"Histone lysine demethylases and their functions in cancer","volume":"148","author":"Sterling","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib132","first-page":"11","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","author":"Sun","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib133","first-page":"158","article-title":"Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators","volume":"25","author":"Takahashi","year":"2023","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.critrevonc.2025.105083_bib134","first-page":"1","article-title":"TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression","volume":"6","author":"Takayama","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.105083_bib135","doi-asserted-by":"crossref","first-page":"39954","DOI":"10.1074\/jbc.M112.395574","article-title":"Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem\/progenitor cells with 5-Aza-2\u2032-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis","volume":"287","author":"Tian","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.105083_bib136","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/molecules28073043","article-title":"BET bromodomain inhibitors: novel design strategies and therapeutic applications","volume":"28","author":"To","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2025.105083_bib137","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib138","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax\u00ae, NSC 630176, FR901228, FK228, Depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"Vandermolen","year":"2011","journal-title":"J. Antibiot."},{"key":"10.1016\/j.critrevonc.2025.105083_bib139","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1172\/JCI126327","article-title":"Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1","volume":"130","author":"Wang","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.105083_bib140","article-title":"The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib141","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.105083_bib142","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib143","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between Polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105083_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.624742","article-title":"Hypomethylating agents and immunotherapy: therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Wong","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.105083_bib145","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105083_bib146","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105083_bib147","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.apsb.2021.08.028","article-title":"A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities","volume":"12","author":"Xie","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2025.105083_bib148","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105083_bib149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/epi.15.94","article-title":"The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors","volume":"8","author":"Yang","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.critrevonc.2025.105083_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105937","article-title":"RNA methylation and cancer treatment","volume":"174","author":"Yang","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib151","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10637-017-0553-x","article-title":"A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Yu","year":"2018","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2025.105083_bib152","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1111\/cas.15122","article-title":"The EZH2 inhibitor tazemetostat upregulates the expression of CCL17\/TARC in B-cell lymphoma and enhances T-cell recruitment","volume":"112","author":"Yuan","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.105083_bib153","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.18632\/oncotarget.13773","article-title":"Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells","volume":"8","author":"Zeng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105083_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddiscovery.2016.36","article-title":"Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6","volume":"2","author":"Zhang","year":"2016","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.critrevonc.2025.105083_bib155","first-page":"98","article-title":"Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer","author":"Zhang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2025.105083_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1470148","article-title":"DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.105083_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-020-0218-z","article-title":"BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling","volume":"9","author":"Zhou","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2025.105083_bib159","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-12-386","article-title":"Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines","volume":"12","author":"Zopf","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.105083_bib160","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-09-2917","article-title":"Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer","volume":"16","author":"Zoubeidi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105083_bib161","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:02:31Z","timestamp":1773932551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":161,"alternative-id":["S1040842825004718"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105083","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic approaches to prostate cancer: Present landscape and future prospects","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105083"}}